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Abstract
Aims
Urocortin-1 (Ucn-1) is an endogenous peptide that protects heart from ischemia and reper-
fusion (I/R) injuries. Ucn-1 is known to prevent cardiac cell death, but its role in the transcrip-
tion of specific genes related to survival signaling pathway has not been fully defined. The
aim of this study was to investigate the molecular signaling implicated in the improvement of
cardiac myocytes survival induced by Ucn-1.
Methods and Results
Ucn-1 administration before ischemia and at the onset of reperfusion, in rat hearts perfused
in Langendorff system, fully recovered heart contractility and other hemodynamic parame-
ters. Ucn-1 enhanced cell viability and decreased lactate dehydrogenase (LDH) release in
adult cardiac myocytes subjected to simulated I/R. Annexin V-FITC/PI staining indicated
that Ucn-1 promoted cell survival and decreased cell necrosis through Epac2 (exchange
protein directly activated by cAMP) and ERK1/2 (extracellular signal–regulated kinases 1/2)
activation. We determined that Ucn-1 shifted cell death from necrosis to apoptosis and acti-
vated caspases 9 and 3/7. Furthermore, mini-array, RT-qPCR and protein analyses of apo-
ptotic genes showed that Ucn-1 upregulated the expression of CD40lg, Xiap and BAD in
cells undergoing I/R, involving Epac2 and ERK1/2 activation.
Conclusions
Our data indicate that Ucn-1 efficiently protected hearts from I/R damage by increasing the
cell survival and stimulated apoptotic genes, CD40lg, Xiap and BAD, overexpression
through the activation of Epac2 and ERK1/2.
PLOS ONE | DOI:10.1371/journal.pone.0147375 February 3, 2016 1 / 16
OPEN ACCESS
Citation: Calderón-Sánchez E, Díaz I, Ordóñez A,
Smani T (2016) Urocortin-1 Mediated
Cardioprotection Involves XIAP and CD40-Ligand
Recovery: Role of EPAC2 and ERK1/2. PLoS ONE
11(2): e0147375. doi:10.1371/journal.pone.0147375
Editor: John Calvert, Emory University, UNITED
STATES
Received: September 25, 2015
Accepted: January 4, 2016
Published: February 3, 2016
Copyright: © 2016 Calderón-Sánchez et al. This is
an open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This study was supported by Spanish
Ministry of Economy and Competitiveness [BFU2013-
45564-C2-2-P]; Institute of Carlos III and
Cardiovascular Network "RIC" [RD12/0042/0041;
PI12/00941]; and from the Andalusia Government
[PI-0108-2012; P10-CVI-6095].
Competing Interests: The authors have declared
that no competing interests exist.
Abbreviations: cAMP, cyclic AMP; BAD, Bcl-2-
associated death promoter; CD40lg, CD40 ligand;
Introduction
Despite the considerable advances that have been made in the field of myocardial protection,
ischemic heart disease represents a major public health problem and the main cause of mortal-
ity in the industrialized world [1]. Percutaneous transluminal angioplasty, fibrinolysis and car-
dioplegic solutions are some of the strategies developed to preserve the myocardial viability
from ischemia. All these procedures involve myocardial reperfusion/reoxygenation after an
ischemic episode. However, the subsequent reperfusion also activates various injury responses
leading to necrosis, apoptosis and general heart dysfunction [1, 2].
Special interest has been made toward the endogenous protection elicited by the heart as a
potent approach to limit heart lesions from I/R insult. In the last two-decade, urocortin pep-
tides (Ucn-1, Ucn-2, Ucn-3), which belongs to the corticotropin-releasing factor (CRF) family
[3], have emerged as a potential therapeutic agonist that improves heart performances and pro-
tects heart from I/R injuries [4]. In the cardiovascular system, urocortin binding to its G pro-
tein–coupled receptor (CRF-R2) is known to enhance cAMP production [5], which is
classically related to PKA activation. However, a guanine nucleotide exchange factor (GEF)
also activated directly by cAMP, named exchange protein activated by cyclic AMP (Epac)
emerged as a new player of several cAMP-regulated processes in heart such as heart inotropism
[6], cardiac myocytes hypertrophy [7], and Ca2+ handling in cardiac myocytes [8]. Previously,
we have described that Epac and ERK1/2 are involved in urocortin-induced positive inotrop-
ism in rat hearts [9]. However, Epac role in cardioprotection has been barely studied.
Different mechanisms are implicated in the cardioprotection afforded either by Ucn-1 or
Ucn-2, involving the rapid activation of protective signaling pathways [10], calcium-indepen-
dent phospholipase A2 (iPLA2) and protein kinase C epsilon (PKCε) [11], or ERK1/2 [12, 13],
among others. Urocortin also regulated cell survival and apoptosis during I/R injury, through
caspase 3 inhibition [10], STAT3 [14] or p38MAPK activation [15]. We have shown recently
that Ucn-1 administration only at the beginning of the reperfusion preserved heart contractility
by the improvement of intracellular Ca2+ handling, which included the recovery of cells excit-
ability, the inhibition of diastolic Ca2+ increase and the regulation of Na+/Ca2+ exchanger [16].
Herein, we explored the molecular pathway involved in Ucn-1 evoked heart protection with
special emphasis on Epac and ERK1/2 on their role in cardiac myocytes survival. We also
examined the effect of Ucn-1 on cell death pathways and its regulation of apoptotic genes,
CD40lg, Xiap and BAD.
Materials and Methods
All the experiments with animals were performed in accordance with the recommendations of
the Royal Decree 53/2013 in agreement to the Directive 2010/63/EU of the European Parlia-
ment and approved by the local Ethics Committee on human Research of the “Virgen del
Rocio” University Hospital of Seville and the Animal Research Committee of the University of
Seville.
Ex vivo Langendorff-perfused rat heart
Adult maleWistar rats weighing 250–350 g were heparinized (4 IU/g i.p.) and anaesthetized by
intraperitoneal administration of an overdose of sodium thiopental (200 mg/Kg). The hearts
were quickly removed, mounted on the aortic cannula of the Langendorff perfusion system
apparatus and perfused with an oxygenated Krebs- Henseleit buffer (en mM; 118 NaCl, 4.7
KCl, 1.25 CaCl2, 1.2 KH2PO4, 1.2 MgSO4, 25 NaHCO3, and 5 glucose) as described previously
[9, 17]. Before each experimental protocol was initiated, the isolated hearts were set at a mean
arterial pressure of 60–80 mmHg and were allowed to stabilize at 37°C for 40 to 60 minutes.
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CRF, corticotropin-releasing factor; CRF-R1,2,
corticotropin releasing factor receptor 1,2; dP/dt,
derivative of left ventricular pressure; Epac, exchange
protein directly activated by cAMP; ERK1/2,
extracellular signal–regulated kinases ½; GEF,
guanine nucleotide exchange factor; I/R, ischemia/
reperfusion; LDH, lactate dehydrogenase; LVDP, left
ventricular developed pressure; LVEDP, left
ventricular end diastolic pressure; MAPK, mitogen
activated protein kinase; PKA, protein kinase A;
PKCε, protein Kinase C epsilon; Ucn-1, urocortin-1;
Xiap, X-linked inhibitor of apoptosis protein.
Chart Powerlab software (ADInstruments) was used for continuous recording throughout the
experiments of heart rate, left ventricular developed pressure (LVDP), and maximum positive
and negative derivative of left ventricular pressure (±dP/dt). The heart contractility under dif-
ferent treatments was evaluated by the analysis of +dP/dt, which corresponds to % increase of
+dP/dt normalized to basal value after the period of stabilization.
The standard protocol of ischemia/reperfusion in perfused hearts was followed as described
previously [16]. Group 1 of I/R: After stabilization, rat hearts were exposed to global ischemia
(without aorta perfusion) during 40 minutes and 1 hour of reperfusion with freshly oxygenated
solution. Group 2 corresponds to the pharmacological preconditioning with Ucn-1 (10 nM).
After stabilization, Ucn-1 was applied 20 minutes before ischemia and 30 minutes at the begin-
ning of reperfusion.
Isolation of ventricular myocytes
The hearts were removed and mounted on a Langendorff perfusion apparatus. Ventricular
myocytes were isolated using collagenase type II (251 IU/mL; Worthington Biochemical, Lake-
wood, NJ, USA) as described previously [9]. Subsequently, isolated cells were filtered, centri-
fuged and suspended in Tyrode solution containing (en mM): 130 NaCl, 1 CaCl2, 0.5 MgCl2,
5.4 KCl, 22 glucose, 25 HEPES, 0.4 NaH2PO4, 5 NaHCO3; pH was adjusted to 7.4 with NaOH.
Cardiac myocytes were plated in control solution containing 1.8 mM CaCl2 at 37°C, and were
submitted to a protocol of I/R using a simulated ischemic solution (mM): 142 NaCl, 3.6 KCl,
1.2 MgCl2, 1.8 CaCl2, 20 Hepes, 20 Lactate-Na, 20 sucrose (pH 6.2). Cells were then placed dur-
ing 30 minutes in an incubator of 1% O2 and 5% CO2. Afterward, cells were incubated in con-
trol solution in a 21% O2 and 5% CO2 incubator during 18 hours. All the experiments were
performed on Ca2+-tolerant rod-shaped myocytes.
Treatment protocols
Group 1, control: Untreated cardiac myocytes.
Group 2, I/R: After stabilization in control solution, cells were exposed to simulated ische-
mia solution during 30 minutes followed by 18 hours of reperfusion with freshly control
solution.
Group 3, Ucn-1: Same as group 2, but Ucn-1 (10 nM) was applied 20 minutes before ische-
mia followed by reperfusion.
Group 4, 8CPT: preconditioning with 8CPT (10 μM), specific agonist of Epac: Same as
group 3 but 8CPT was applied instead of Ucn-1.
Group 5 and 6: Cells treated with either ESI-05 (10 μM, Epac2 inhibitor) or PD 098059
(5 μM, ERK1/2 inhibitor) 10 minutes before the addition of Ucn-1 (10 nM) following the
same protocol as in group 3.
Apoptosis and necrosis assays
The level of lactate dehydrogenase (LDH) was detected in supernatant of cells subjected to sim-
ulated I/R protocol according to the manufacturer’s instructions (Promega). Trypan Blue stain-
ing method was also used for detecting cell death in cardiac myocytes undergoing treatment
with I/R ± Ucn-1 (10 nM). Briefly, after each treatment cells were washed three times with
PBS, then cells were bathed in 0.5% of trypan blue for 10 minutes. Based on the classical cell
counting, we acquired 4 random snapshots per each condition using 40x Objective of an Olym-
pus microscope. Maximum projection was recorded and analyzed with “Image J” software to
count the different proportion of trypan positive and negative cells by an investigator blinded
to the treatment conditions. This process was repeated in triplicate for each condition and the
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experiment was replicated on 3 separate occasions. 100% indicates total number of trypan
stained and unstained cells in each condition.
Double staining with annexin V-FITC and propidium iodide (PI) was also performed to
examine apoptosis and necrosis in cultured cardiac myocytes. During apoptosis, an early and
ubiquitous event is the exposure of phosphatidylserine at the cell surface, which is detected
with annexin V-FITC. PI is used to determine the population of cells that have lost membrane
integrity, an indication of late apoptosis or necrosis. Briefly, cardiac myocytes were seeded in a
6-channel μ-Slide (μ-Slide VI 0,4) from IBID. After treatments cardiac myocytes were incu-
bated with 100 μl of the binding buffer supplied in the kit (Cat. 4830-01-K. Trevigen) and 1 μl
of annexin-FITC reagent, during 60 minutes at 25°C. Then PI was added and incubated for 15
minutes and later washed before mounting the slides. Images were taken with confocal micro-
scope Leica TCS SP2 microscopy (Leica). 5 snapshots per condition were acquired using a
HCX PI Apo CS 40x objective in z-stacks intervals, and maximum projection was recorded
and analyzed with “Image J” software to count the different proportion of cells that were
labeled only with annexin (early apoptosis), or with PI and/or annexin and PI (necrosis or late
apoptosis).
Caspase 9, 8 and 3/7 activity
To determine the caspase activity we used the Caspase-Glo assay kit system from Promega;
TB323 for Caspase 3/7, TB332 for Caspase 8, and TB333 for Caspase 9. Protein extracts from
cultured cardiac myocytes were quantified by Bradford (Sigma Aldrich) method and were
diluted at 1.5 μg/μl of protein. 10 μl of protein extract and 10 μl of Caspase-Glo reagent were
added in a 384 flat and white multi-well dish in quadruplicate replicates and incubated for 40
minutes at room temperature. Luminescent signal was detected in a Luminoskan ascent micro-
plate luminometer (Thermo Scientific).
Western Blotting
Protein samples were extracted from cultured and treated cardiac myocytes and 40 μg of pro-
tein were subjected to SDS-PAGE (10% acrylamide) and electrotransferred onto PVDF mem-
branes. Membranes were probed overnight at 4°C with specific primary antibodies in TTBS
with 1% of BSA. CD40lg antibody was from sigma. BAD, phosphoBAD, Xiap, phosphoERK1/2
and ERK1/2 primary antibodies were from Cell Signaling. Detection was performed with the
enhanced chemiluminiscence reagent ECL-plus (Amersham Bioscience) in the ImageQuant
LAS 4000 mini (GE Healthcare). For quantification, the images were analyzed with “Image J”
software using alpha-tubulin (Sigma) or GAPDH (Genetex) as housekeeping loading control.
Analysis of mRNA expression
Total RNA was extracted from cultured cardiac myocytes using the RNeasy kit (Qiagen)
according to the manufacturer’s instructions. RNA purity and concentration were assessed by
measuring absorption at 260 nm and 280 nm. 1 μg of RNA were retro-transcribed to cDNA
with the RT quantitec kit (Qiagen). qRT-PCRs were performed with the use of a Prism
7900HT Sequence Detection System, Taqman primers and probes technologies (Applied Bio-
systems). Fold change in gene expression was calculated using the comparative cycle threshold
CT (ΔΔCT) method.
For apoptosis PCR array, we used plates from SA Biosciences (Cat. PAHS-012). Total RNA
from Ucn-1 treated and no-treated cardiac myocytes (as described in cell treatment protocols)
submitted to I/R was extracted and reverse transcribed into cDNA with the use of an RT2 First
Strand Kit (SA Biosciences). The templates were combined with an RT2 SYBR Green qPCR
Urocortin-1 and Cardioprotection
PLOS ONE | DOI:10.1371/journal.pone.0147375 February 3, 2016 4 / 16
Master Mix (SA Biosciences), and then equal aliquots of this mixture (25 μl) were added to
each well of the same PCR Array plate that contained the pre-dispensed gene-specific primer
sets. The qRT-PCR quantification was performed as described above by ΔΔCT method.
Statistical analysis
Data analysis was carried out using SigmaPlot software, version 11.0. A sample size calculation
was performed prior the start of this study. Group data are presented as mean ± S.E.M. Single
or paired Student's t test was used to determine the statistical significance of the obtained data.
The significance between multiple groups was evaluated using ANOVA followed by Tukey
multiple comparison post hoc tests for comparing different groups. Data marked by , , 
were considered significantly different at p<0.05, p<0.01 and p<0.001 respectively.
Results
Urocortin-1 improves the hemodynamic performances in isolated rat
hearts submitted to ischemia and reperfusion protocol
The protective effects of Ucn-1 on heart contractility were analyzed in ex vivo Langendorff-per-
fused rat hearts submitted to I/R. Fig 1A–1C shows that hearts exposed to 40 minutes of ische-
mia and 60 minutes of reperfusion (I/R) suffered a significant decrease in the left ventricular
developed pressure (LVDP) as well as in the positive and negative maximum derivative of left
ventricular pressure (±dP/dt), indicating significant loss in heart function. The addition of
Ucn-1 (10 nM) 20 minutes before ischemia and 30 minutes at the beginning of reperfusion
recovered significantly LVDP and ±dP/dt as shown in Fig 1B and 1C. The comparison of
superimposed LVDP after I/R obtained either from untreated hearts or from hearts treated
with Ucn-1, revealed that the peptide decreased the time-to-peak of LVDP, recovered fully its
amplitude and accelerated the relaxation comparing to untreated hearts submitted to I/R (Fig
1D and 1E).
Furthermore Fig 2 shows that Ucn-1 administration recovered completely +dP/dt which
was sustained in the maximum level in reperfusion (Fig 2A), and improved others hemody-
namic parameters such as the left ventricular end diastolic pressure (LVEDP) (Fig 2B), and the
coronary vascular resistances whose progressive rise observed in reperfusion was prevented sig-
nificantly by Ucn-1 (Fig 2C). These cardioprotective effects of Ucn-1 were even maintained 30
minutes after washing out the peptide.
Urocortin-1 promotes cell survival, regulates apoptosis and necrosis in
cardiac myocytes exposed to I/R
To further evaluate the cardioprotection exerted by Ucn-1, we examined cardiac myocytes via-
bility using several approaches. First, we estimated trypan blue staining in cardiac myocytes
subjected to I/R. Fig 3A shows a significant increase in trypan blue positive staining in cells
submitted to I/R as compared to control. However, cells pretreatment with Ucn-1 (10 nM)
decreased significantly the number of trypan blue positive cells. Next, to verify the trypan blue
finding cell death was also assessed by measurement of LDH release. Cells exposition to I/R
resulted in significant increase of LDH levels, meanwhile Ucn-1 (10 nM) significantly reduced
the release of LDH during I/R (Fig 3B).
In addition, we used annexin V-FITC staining to label apoptotic cells in combination with
red-fluorescent PI (propidium iodide) that stains late apoptotic/necrotic cells. Representative
images and data analysis in Fig 4A and 4B show that cells subjected to I/R resulted in a signifi-
cant loss of cell viability and a marked increase of the PI positive population, reflecting higher
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level of cell death by necrosis. Whereas, Ucn-1 (10 nM) treatment of cardiac myocytes exposed
to I/R increased the amount of viable cells. Interestingly, Ucn-1 promoted a significant decrease
in PI positive cells (necrosis) but it increased early apoptosis as indicated by annexin V positive
Fig 1. Effect of urocortin-1 on contractility in ex vivo isolated perfused rat hearts. A) Representative
original recording of the left ventricular developed pressure (LVDP, upper tracing), and the derivative of left
ventricular pressure (dP/dt, lower tracing) in Langendorff perfused heart before ischemia (control) and in
reperfusion after 40 minutes of global ischemia (reperfusion). B) Representative recording in reperfusion of
LVDP and dP/dt from heart treated 20 minutes with urocortin-1 (Ucn-1) before ischemia and 30 minutes at the
onset of reperfusion. C) Graph shows summary data of LVDP expressed as the difference between
maximum and basal values from control, ischemia and reperfusion (I/R), and Ucn-1 treated hearts.D)
Superimposed representative single traces of LVDP from control, reperfusion after ischemia (I/R), and in
reperfusion from Ucn-1-treated hearts. E) Summary data of time-to-peak of LVDP. Values are means ± s.e.m
from 6 hearts. “***” indicates significance at p<0.001 of +Ucn-1 vs I/R.
doi:10.1371/journal.pone.0147375.g001
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Fig 2. Urocortin-1 improves the hemodynamic function of Langendorff perfused rat hearts submitted
to ischemia and reperfusion (I/R). A) Graph illustrates the contractility expressed as +dP/dt (%) in hearts
submitted to ischemia/reperfusion protocol (I/R, full diamond, n = 9), and in hearts treated with 10 nM Ucn-1
(+Ucn-1, open square, n = 8). Ucn-1 were applied 20 minutes before ischemia and 30 minutes in reperfusion
as indicated. B) Summary data of the left ventricular end diastolic pressure (LVEDP, mmHg) in the same
conditions as in “A”. C) Shows the mean of vascular resistance (mmHg*min/ml) changes during the same
Urocortin-1 and Cardioprotection
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experiments described in “A”. Dashed lines indicate basal control values for each hemodynamic parameter.
Values are means ± s.e.m. “*” indicates significance at p<0.05 of I/R vs +Ucn-1.
doi:10.1371/journal.pone.0147375.g002
Fig 3. Urocortin-1 increases cell survival, inhibits LDH release by stimulation of ERK1/2
phosphorylation in reperfusion. A)Graph summarizes the amount of isolated adult cardiac myocytes
stained with trypan Blue. Cells were submitted to I/R (30 minutes/18 hours each) ± Ucn-1 (10 nM). B) Bar
graph shows the level of LDH release in cardiac myocytes from 5 independent cultures, in control and after I/
R (30 minutes/18 hours each) ± Ucn-1 (10 nM). Ucn-1 was also applied in the presence of ERK inhibitor,
5 μMPD 098059 (Ucn-1 + PD), or with Epac2 inhibitor, 5 μMESI-05 (Ucn-1+ESI). C)Western blot andD)
summary data of ERK 1/2 phosphorylation in control cardiac myocytes and in cells exposed to I/R (30
minutes/18 hours each). Cells were treated with Ucn-1 (10 nM) or with 8CPT (10 μM) alone or in the presence
of 5 μMPD 098059 indicated as Ucn-1 + PD, 8CPT + PD respectively. Data are given as means ± s.e.m.
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staining, suggesting that Ucn-1 enhanced cell viability and shifted cell death from necrosis to
apoptosis in cells exposed to I/R. Next, we examined caspases activity using an enzymatic-
based assay. Fig 4C shows that Ucn-1 enhanced significantly caspase 9 and 3/7 activity in cells
exposed to I/R, consistent with annexin-FITC V/PI observations. However, the activation of
caspase 8 was not affected by Ucn-1 as shown in S1 Fig.
Fig 4. Urocortin-1 effects on cell death and apoptosis. A)Representative images of isolated adult cardiac
myocytes submitted to I/R (left) and treated with Ucn-1 (right), stained with annexin V-FITC (green) and PI
(red). B) Shows the summary data from untreated cells (control) and cells exposed to I/R (30 minutes/18
hours each) ± Ucn-1 (10 nM) alone or in presence of 5 μMPD 098059 (Ucn-1 + PD) or 10 μMESI-05 (Ucn-1
+ ESI). 8CPT bars are for cells exposed to I/R (30 minutes/18 hours each) treated with 8CPT (10 μM). White
bars indicate viable cells; black bars are for necrosis; and grey bars indicate apoptosis. n = 5 cultures. “*”
indicates significance at p<0.05 of I/R vs control. “#” indicates significance at p<0.05 of Ucn-1 and 8CPT
comparing to I/R. “&” indicates significance at p<0.05 of Ucn-1 comparing to Ucn-1+PD or to Ucn-1+ESI. C)
Graphs show caspase 9 and 3/7 activation in similar experiments as in “B. n = 5 cultures. Data are given as
means ± s.e.m. “*”, “**” and “***” indicate significance at p<0.05, p<0.01 and p<0.001 respectively.
doi:10.1371/journal.pone.0147375.g004
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Signaling pathway involved in the protection afforded by urocortin-1
We examined the contribution of ERK1/2 pathway in Ucn-1 cardioprotective effects. Fig 3C
and 3D shows that the addition Ucn-1 (10 nM) enhanced the phosphorylation of both ERK
p42 and p44 isoforms in isolated cardiac myocytes submitted to I/R. Ucn-1 induced phorphor-
ylation of ERK 1/2 was potently reduced by ERK1/2 inhibitor PD 098059 (5 μM) (17). Interest-
ingly, cells pretreatment with PD 098059 prevented Ucn-1 cytoprotective effects as LDH
release (Fig 3B), cell viability and necrosis (Fig 4B) and caspase 9 and 3/7 activation (Fig 4C).
Because Epac activates the Ras1-ERK1/2 pathway [18], we also investigated whether Epac
signals ERK1/2 activation in Ucn-1 treated cardiac myocytes. Fig 3C and 3D shows that cells
incubation with 8CPT (10 μM), the specific agonist of Epac [19], also stimulated ERK1/2 phos-
phorylation in I/R, which was inhibited significantly by PD 098059. Fig 4B also shows that
8CPT (10 μM) mimicked the effect of Ucn-1 on cell viability, apoptosis and necrosis. To fur-
ther confirm Epac role in Ucn-1 action we tested ESI-05 (10 μM), considered as the most spe-
cific inhibitor of Epac2 [20]. As shown in Figs 3B and 4B, cells pretreatment with ESI-05
abolished Ucn-1 cytoprotective effects on LDH release cell viability, apoptosis and necrosis.
The addition of PD 098059 or ESI-05 in cardiac myocytes subjected to I/R, but in the absence
of Ucn-1, didn’t change cell viability, apoptosis and necrosis as illustrated in S2 Fig.
Urocortin-1 alters apoptotic gene expression
To get more insight into the mechanism involved in Ucn-1 cytoprotection and apoptosis, we
analyzed the expression of 84 key genes involved in apoptosis using a PCR based micro-array
technique. S3 Fig shows that the expression of several genes changed in cells undergoing the
same protocol of I/R and incubated with Ucn-1 (10 nM) comparing to untreated cells. Next,
we verified by RT-PCR analysis the impact of I/R on CD40lg, Xiap and BAD genes expression
and their possible modulation by Ucn-1. We observed that mRNA expression of CD40lg (Fig
5A), Xiap (Fig 5B) and BAD (Fig 5C) were significantly decreased in cells exposed to I/R,
whereas cells treatment with Ucn-1 recovered completely these genes expression. The effect of
Ucn-1 on CD40lg and Xiap were abolished by ERK1/2 inhibition with PD 098059 (5 μM).
Meanwhile, Epac2 inhibition with ESI-05 (10 μM) blocked the effect of Ucn-1 on Xiap but not
on CD40lg expressions. Furthermore, the evoked upregulation of BAD by Ucn-1 was inhibited
in the presence of ESI-05 (10 μM) but not when cells were treated with PD 098059 (5 μM).
Next, the analysis of protein expression showed that CD40lg, Xiap and Bad levels were not
significantly affected by I/R, however the administration of Ucn-1 enhanced significantly the
expression of CD40lg and Xiap protein in ERK1/2 dependent manner, since treatment with
PD 098059 (5 μM) prevented Ucn-1 effects as shown in Fig 5D, 5F and 5G). At the same time,
Ucn-1 enhanced potently BAD protein expression comparing to untreated cells exposed to I/R
(Fig 5E and 5H), which was inhibited by ESI-05 (10 μM) but not by PD 098059 (5 μM) con-
firming the implication of Epac2 but not ERK1/2. 8CPT (10 μM) cells treatment also mimicked
the effect of Ucn-1 by enhancing BAD expression. Since BAD activity depends on its phos-
phorylation state, we further examined the amount of serine phosphorylated protein in Ucn-1
treated cardiac myocytes. Fig 5E and summary data in S4 Fig show that Ucn-1 didn’t affect
BAD phosphorylation, although the amount of free activated protein was significantly
increased in cells treated with Ucn-1 and 8CPT compared to cells submitted only to I/R.
Discussion
Clinical search for new heart protection strategies and new endogenous cardioprotector is still
of major relevance. There is continuous interest in developing novel therapeutic targets that
potentially protect the heart against I/R injuries and complications [21, 22]. Several studies
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have demonstrated that different pre or post- conditioning strategies effectively protect the
heart and reduce infarct size after an ischemic insult [23]. Urocortin is recognized as a potential
therapeutic agent thanks to its powerful cardioprotective properties, involving different intra-
cellular signaling pathways [24, 25].
Our experimental data from Langendorff-perfused rat hearts showed that Ucn-1, given
both before and after a global ischemic insult, was able to recover heart contractility, to pre-
serve vascular resistance, and to improve the ventricular diastolic pressure, indicative of its pre-
vention of hypercontracture and rigor. Ucn-1 effectively sustained rat hearts hemodynamics
Fig 5. Urocortin-1 effects on the expression of CD40lg, Xiap, and BAD. A, B and C) Bar graphs show
mRNA levels of CD40lg, Xiap and BAD respectively from 5 cultures of cardiac myocytes in control and after I/
R (30 minutes/18 hours each) ± Ucn-1. Ucn-1 (10 nM) was also applied in presence of 5 μMPD 098059 (Ucn-
1 + PD) or 5 μMESI-05 (Ucn-1 + ESI). D to H) Representative western blot and summary data of CD40lg,
Xiap, and BAD in similar conditions as in A, B and C. 8CPT (10 μM) was applied instead of Ucn-1 to activate
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properties and protected it from I/R injury consistent with the effect of Ucn-2 described in pre-
vious studies [24, 25].
The degree of cardiac dysfunction after I/R injury reflects the level of cardiac myocytes lesion
related to subsequent cell death, scare formation and a worse long-term outcome. Here, we dem-
onstrated that Ucn-1 exerted significant cytoprotective effects as it efficiently decreased trypan blue
cell staining, inhibited LDH release, and enhanced cell viability by the modulation of apoptosis and
necrosis. Ucn-1 administration decreased significantly necrotic cells but it increased apoptotic cells
number. In fact, while Ucn-1 increased cell viability it shifted cell death from necrosis to apoptosis,
a more programmed and controlled cell death. Ucn-1 promotion of apoptosis in detriment of
necrosis is supposed more beneficial to reduce the impact of I/R lesions as discussed earlier [26].
Apoptosis is a known form of cell death mediated through sequential activation of the caspase cas-
cade. Consistently, Ucn-1 stimulated caspase 3/7 and caspase 9, but not caspase 8 that is associated
to death receptors-mediated apoptosis [27]. These data is contrary to Ucn-2 reduction of caspase 3
levels due to a significant induction of natriuresis and decreased tissue mediators of inflammation
[10, 28]. Ucn-1 stimulation of caspase 3/7 and 9 findings was supported with Ucn-1 regulation of
apoptotic genes expression. Actually, we observed that cardiac myocytes incubation with Ucn-1
preserved the expression of the well known anti-apoptotic genes CD40lg and Xiap [29, 30], as well
as the pro-apoptotic BAD [29], which were down-regulated in cells exposed to I/R. Furthermore,
at protein levels Ucn-1 also upregulated Xiap, CD40lg, and BAD. The levels of BAD phosphoryla-
tion known to allow its confinement to the cytoplasm and the inhibition of BAD-dependent death
[31, 32], was not affected in Ucn-1 treated cells. However, the increase in total amount of BAD pro-
tein under Ucn-1 treatment was accompanied also by an increase in the amount of dephosphory-
lated (free) BAD protein, which might explain the observed apoptosis annexin/PI and caspase
experiments. Similarly, the activation of BAD by Ucn-1 and Ucn-2 was previously described in
macrophage [33] but not yet in heart. On the other hand, Ucn-1 upregulation of anti-apoptotic
genes CD40lg and Xiap explains its beneficial effects on cell survival and necrosis. To our knowl-
edge, this study is the first to involve CD40lg and Xiap in Ucn-1 cardioprotective effects. In this
study, we noticed that the changes in mRNA levels of apoptotic genes during cells exposition to in
I/R were more evident than at the protein levels, which could be due to the complex mechanism of
post-transcriptional mechanisms involved in turning mRNA into protein [34].
Moreover, we demonstrated that Ucn-1 implicated Epac2 and ERK1/2 in its cardioprotec-
tive actions. ERK1/2 role as a survival pathway in cardiac cells is widely accepted [10–12], nev-
ertheless only few reports directly investigated its activation during reperfusion [35, 36]. In this
study, we demonstrated that under I/R, Ucn-1 activated significantly ERK1/2, whose inhibition
by PD 098059 dramatically prevented Ucn-1 protective effects in Langendorff perfused hearts
(data not shown), and abolished Ucn-1 cytoprotection action supporting the importance of
ERK1/2 in mediating urocortin effects, in accordance with others studies [12, 13]. Indeed, we
demonstrated that ERK1/2 are also implicated in Ucn-1 inhibition of LDH release, cell viabil-
ity, caspase activation, and in the modulation of CD40lg and Xiap expression. Furthermore,
very few studies have focused on the role of Epac in urocortin signaling pathway [9, 37, 38].
However, the role of Epac in cardioprotection is still under debate. Recently, a cardioprotective
role of β-adrenergic signaling via cAMP/Epac/Rap1/Rac/ERK pathway has been described in
mice [39]. Epac activation was also associated with cardiac myocytes protection from nitric
oxide-induced apoptosis [39, 40]. Here, we provided different data indicating Epac2 involve-
ment in Ucn-1 cardioprotective effects by the use of ESI-05 as a selective inhibitor for Epac2
isoform (for review see [20]). We found that ESI-05 inhibited the effects of Ucn-1 on LDH
release and prevented Ucn-1 restoration of Xiap and BAD expression. Our data suggest for the
first time an important role for Epac2 in Ucn-1 heart improvement from I/R lesions, which is
consistent with the increasing numbers of studies that propose an important role of Epac in
Urocortin-1 and Cardioprotection
PLOS ONE | DOI:10.1371/journal.pone.0147375 February 3, 2016 12 / 16
heart [6–8, 41]. Finally, Epac as a GTP exchange factor is known to activate Rap1-GTPase by
catalyzing the formation of Rap1-GTP and further stimulation of ERK. Herein, we demon-
strated that Epac activation with 8CPT mimicked the effect of Ucn-1 on ERK1/2 activation in
I/R, which suggested that Epac is upstream of ERK1/2 signaling pathway.
In conclusion, we demonstrated that the administration of Ucn-1 before ischemia and dur-
ing the first minutes of re-oxygenation produced significant long-lasting protective effects,
mediated by a complex signaling pathway that involve Epac2 and ERK1/2. Ucn-1 promotion
of cell survival and apoptosis might be beneficial since apoptosis is considered a highly regu-
lated energy-consuming process, required for controlled and programmed cell death, which
will limit cardiac cell loss and posterior inflammation processes in I/R. Together with the other
cardioprotective actions of urocortin including vasorelaxation of human coronary artery [42],
the positive inotropism [9], and the decrease in renin activity, aldosterone, vasopressin,
endothelin1 and atrial and B-type natriuretic peptides [43], all hallmark events shown to
diminish the destroying effect of I/R injury, certainly confirm urocortin as a valuable target for
the treatment of diseases associated with cardiac dysfunction under post-ischemic insults.
Supporting Information
S1 Fig. Urocortin-1 doesn’t activate caspase 8.Graph shows caspase 8 activity analyzed from
cells exposed to ischemia and reperfusion (I/R; 30 min/18 h each) ± urocortin-1 (Ucn-1, 10 nM).
Ucn-1 (10 nM) was also applied in presence of 5 μMPD 098059 (Ucn-1+PD). Data are given as
means ± s.e.m. n = 5 cultures. “ns” indicates that values are not significantly different from control.
(TIF)
S2 Fig. Effects of PD 098059 and ESI-05 on cell viability, apoptosis and necrosis. Graph
shows summary data from untreated cells (control), cells exposed to I/R (30 minutes/18
hours), cells exposed to I/R in presence of 5 μM PD 098059 (I/R+ PD) or 10 μM ESI-05 (I/R
+ ESI). “” indicates significance between control and different treatment at p<0.05. “ns” indi-
cates that values are not statistically different between I/R and I/R+ESI or I/R +PD. Values are
means ± s.e.m. n = 4 cultures.
(TIF)
S3 Fig. Fold change of the expression of 84 key genes involved in apoptosis. PCR-based
array was performed in samples from cardiomyocytes exposed to I/R and treated or not with
Ucn-1 (10 nM) as described in cell treatment protocols in material and methods.
(TIF)
S4 Fig. Urocortin-1 effects BAD phosphorylation. A) Bar graph shows the analysis of phos-
pho-BAD level from western blot experiments.Protein samples were from cells exposed to
ischemia and reperfusión (I/R; 30 min/18 h each) ± urocortin-1 (Ucn-1, 10 nM). Ucn-1 (10
nM) was also applied in presence of 5 μM PD 098059 (Ucn-1+PD) and 5 μM ESI-05 (Ucn-1
+ESI). 8CPT (10 μM) was applied instead of Ucn-1 to activate Epac B) Analysis of total BAD
and non phosphorylated free BAD in the same experiments as in “A”. Values are means ± s.e.
m. from 3 different experiments.
(TIF)
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